Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 8/20 | 0.49 |
| ▸ | CA9 | Q16790 | 8/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.49 |
| ▸ | SORD | Q00796 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994964 | 0.78 | CA9 (0.51) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL15842410 | 0.77 | MAOB (0.47) | CA12CA9MAOBAKR1B1HSD17B3 | |
| SCHEMBL2985971 | 0.76 | CA12 (0.50) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL21648244 | 0.76 | CA12 (0.74) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL3018453 | 0.76 | CA12 (0.65) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL4077549 | 0.76 | CA12 (0.65) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL21629542 | 0.76 | CA12 (0.72) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL759601 | 0.76 | CA12 (0.64) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL27771665 | 0.74 | CA12 (0.45) | CA12CA9MAOBAKR1B1ALDH2 | |
| SCHEMBL4077626 | 0.74 | CA12 (0.48) | CA12CA9MAOBAKR1B1ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137371-A1 | Novel Pharmaceutical Compounds | LTC4S, LTA4H, LTB4R2 | CA12 3849/4885CA9 2746/4885MAOB 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.